Chemotherapy-free treatment targeting fusions and driver mutations in <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma, a case series
Maahum Mehdi(Medical College of Wisconsin), Mandana Kamgar(Medical College of Wisconsin), Gulrayz Ahmed(Medical College of Wisconsin), Beth Erickson(Medical College of Wisconsin), Susan Tsai(The Ohio State University Wexner Medical Center), Callisia N. Clarke(Medical College of Wisconsin), Razelle Kurzrock(Medical College of Wisconsin), James P. Thomas(Medical College of Wisconsin), Kathleen K. Christians(Medical College of Wisconsin), Thomas McFall(Salk Institute for Biological Studies), Douglas B. Evans(The University of Texas MD Anderson Cancer Center), Aniko Szabo(Medical College of Wisconsin), Aditya Shreenivas(City Of Hope National Medical Center), William A. Hall(Medical College of Wisconsin), Bicky Thapa(Cleveland Clinic), Ben George(Medical College of Wisconsin)
Cited by 5
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Epstein-Barr Virus and Cancer
|Clinical Cancer Research|2004|795
Review of precision cancer medicine: Evolution of the treatment paradigm
|Cancer Treatment Reviews|2020|747
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
|Nature Medicine|2019|710